Kexing Biopharm Forms Strategic Partnership with IQVIA for Global Expansion Efforts
In a significant move towards enhancing its international reach, Kexing Biopharm, a prominent biopharmaceutical company, has announced a comprehensive strategic partnership with IQVIA, a leading global provider of clinical research services. This collaboration aims to accelerate Kexing's global clinical development, regulatory approvals, and commercialization of its innovative drugs and biosimilars, particularly focusing on Europe and other regulated international markets.
Over the past few years, Kexing Biopharm has made major strides in establishing a unique globalization platform that merges advanced feasibility (FE) capabilities with swift commercial execution. The firm has successfully supported the overseas market entry of multiple high-quality pharmaceutical products. Notably, nab-paclitaxel has gained fast-track approval and market introduction in several key countries. Meanwhile, Kexing is vigorously progressing its FE pipeline, targeting therapeutic areas such as antiviral treatments, oncology, immunosuppressants, and metabolic diseases.
This alliance harnesses IQVIA's extensive expertise in global clinical study design, regulatory strategy, and data-driven insights. By integrating Kexing's innovative product pipeline with IQVIA's comprehensive global operational infrastructure, the two companies aim to enhance study efficiencies and accelerate access to international markets. This partnership is expected to significantly bolster Kexing’s global development capabilities and expedite its transition into an international biopharmaceutical innovator.
During the signing ceremony, Brian Mi, Chairman of IQVIA Asia Pacific, highlighted Kexing’s rapid progress in commercialization and product innovation abroad, stating that this collaboration would open new avenues for both parties. Yanqing Zhao, CEO of Kexing Biopharm, emphasized that IQVIA's global clinical data resources, insights into patient situations, and regulatory knowledge will play a pivotal role in optimizing development strategies, improving success rates, and speeding up global approval timelines.
Kexing Biopharm is dedicated to innovation within the biopharmaceutical sector, focusing primarily on the research, development, production, and distribution of recombinant protein drugs and microbiological preparations. Its therapeutic focus encompasses antiviral therapies, treatments for tumors, autoimmune conditions, metabolic diseases, and other areas, striving to build cutting-edge biotechnological platforms for new proteins, antibodies, nucleic acids, and other medications. Underneath its platform-driven development model termed “Innovation+Internationalization,” the company explores the comprehensive application of biotechnology across the expansive health sector.
This strategic partnership reflects Kexing Biopharm’s long-term commitment to expanding internationally through scientific rigor, effective implementation, and robust collaborations. Kexing aims to continue deepening its global partnerships in the future to make high-quality Chinese pharmaceutical innovations accessible to patients worldwide.
In conclusion, the partnership with IQVIA marks a significant milestone for Kexing Biopharm as it endeavors to enhance its global presence and revolutionize the biopharmaceutical landscape with innovative solutions, ultimately benefiting patients across the globe. This dynamic collaboration stands as a testament to Kexing's ambitious goals and its unwavering dedication to innovation in healthcare.
Over the past few years, Kexing Biopharm has made major strides in establishing a unique globalization platform that merges advanced feasibility (FE) capabilities with swift commercial execution. The firm has successfully supported the overseas market entry of multiple high-quality pharmaceutical products. Notably, nab-paclitaxel has gained fast-track approval and market introduction in several key countries. Meanwhile, Kexing is vigorously progressing its FE pipeline, targeting therapeutic areas such as antiviral treatments, oncology, immunosuppressants, and metabolic diseases.
This alliance harnesses IQVIA's extensive expertise in global clinical study design, regulatory strategy, and data-driven insights. By integrating Kexing's innovative product pipeline with IQVIA's comprehensive global operational infrastructure, the two companies aim to enhance study efficiencies and accelerate access to international markets. This partnership is expected to significantly bolster Kexing’s global development capabilities and expedite its transition into an international biopharmaceutical innovator.
During the signing ceremony, Brian Mi, Chairman of IQVIA Asia Pacific, highlighted Kexing’s rapid progress in commercialization and product innovation abroad, stating that this collaboration would open new avenues for both parties. Yanqing Zhao, CEO of Kexing Biopharm, emphasized that IQVIA's global clinical data resources, insights into patient situations, and regulatory knowledge will play a pivotal role in optimizing development strategies, improving success rates, and speeding up global approval timelines.
Kexing Biopharm is dedicated to innovation within the biopharmaceutical sector, focusing primarily on the research, development, production, and distribution of recombinant protein drugs and microbiological preparations. Its therapeutic focus encompasses antiviral therapies, treatments for tumors, autoimmune conditions, metabolic diseases, and other areas, striving to build cutting-edge biotechnological platforms for new proteins, antibodies, nucleic acids, and other medications. Underneath its platform-driven development model termed “Innovation+Internationalization,” the company explores the comprehensive application of biotechnology across the expansive health sector.
This strategic partnership reflects Kexing Biopharm’s long-term commitment to expanding internationally through scientific rigor, effective implementation, and robust collaborations. Kexing aims to continue deepening its global partnerships in the future to make high-quality Chinese pharmaceutical innovations accessible to patients worldwide.
In conclusion, the partnership with IQVIA marks a significant milestone for Kexing Biopharm as it endeavors to enhance its global presence and revolutionize the biopharmaceutical landscape with innovative solutions, ultimately benefiting patients across the globe. This dynamic collaboration stands as a testament to Kexing's ambitious goals and its unwavering dedication to innovation in healthcare.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.